What is the Purpose of this Study?
This study focuses on people who have melanoma (skin cancer) or other cancer with a specific change in the BRAF gene (BRAF alteration) and whose cancer has grown or spread. The study will explore the safety and benefits of an experimental drug called PF-07799544 (blocks a protein involved in cancer growth called 'MEK') in combination with another experimental drug, PF-07799933 (blocks a protein called ‘BRAF’, which is an abnormal protein), and will identify the best doses of these drugs. By giving the study drug PF 07799933 and PF 07799544 as a combination, researchers hope to determine whether the combination of drugs together works better than each drug by itself.
Eligibility
- * Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation
- * Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation
- * For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma
- * For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma,
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute
More about this Clinical Trial
What is the full name of this clinical trial?
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS